CN118973580A - 包含sos1抑制剂和mek抑制剂的组合疗法 - Google Patents

包含sos1抑制剂和mek抑制剂的组合疗法 Download PDF

Info

Publication number
CN118973580A
CN118973580A CN202380032771.6A CN202380032771A CN118973580A CN 118973580 A CN118973580 A CN 118973580A CN 202380032771 A CN202380032771 A CN 202380032771A CN 118973580 A CN118973580 A CN 118973580A
Authority
CN
China
Prior art keywords
inhibitor
sos1
mek inhibitor
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032771.6A
Other languages
English (en)
Chinese (zh)
Inventor
雅各布·哈林
希尔皮·卡雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN118973580A publication Critical patent/CN118973580A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380032771.6A 2022-04-08 2023-04-03 包含sos1抑制剂和mek抑制剂的组合疗法 Pending CN118973580A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329104P 2022-04-08 2022-04-08
US63/329,104 2022-04-08
PCT/US2023/017254 WO2023196218A2 (en) 2022-04-08 2023-04-03 Combination therapies comprising a sos1 inhibitor and a mek inhibitor

Publications (1)

Publication Number Publication Date
CN118973580A true CN118973580A (zh) 2024-11-15

Family

ID=88243402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032771.6A Pending CN118973580A (zh) 2022-04-08 2023-04-03 包含sos1抑制剂和mek抑制剂的组合疗法

Country Status (10)

Country Link
US (1) US20250186453A1 (https=)
EP (1) EP4504197A4 (https=)
JP (1) JP2025513802A (https=)
KR (1) KR20250002214A (https=)
CN (1) CN118973580A (https=)
AU (1) AU2023250314A1 (https=)
CA (2) CA3245730A1 (https=)
IL (1) IL315648A (https=)
MX (1) MX2024012446A (https=)
WO (1) WO2023196218A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271679A1 (en) * 2021-06-21 2022-12-29 Mirati Therapeutics, Inc. Sos1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
AU2021263742A1 (en) * 2020-04-27 2022-09-22 Verastem, Inc. Methods of treating abnormal cell growth
WO2022051565A1 (en) * 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions
WO2022051568A1 (en) * 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions
US12280055B2 (en) * 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
CA3221608A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents
WO2022271679A1 (en) * 2021-06-21 2022-12-29 Mirati Therapeutics, Inc. Sos1 inhibitors

Also Published As

Publication number Publication date
MX2024012446A (es) 2024-11-08
WO2023196218A3 (en) 2023-11-16
JP2025513802A (ja) 2025-04-30
CA3255758A1 (en) 2023-10-12
IL315648A (en) 2024-11-01
US20250186453A1 (en) 2025-06-12
WO2023196218A2 (en) 2023-10-12
AU2023250314A1 (en) 2024-10-03
CA3245730A1 (en) 2023-10-12
KR20250002214A (ko) 2025-01-07
EP4504197A4 (en) 2026-03-18
EP4504197A2 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
JP7546549B2 (ja) 組み合わせ療法
CN112955137B (zh) 组合疗法
JP2024537140A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｏｓ１阻害剤との併用療法
TWI620748B (zh) 氨基噻唑化合物及其用途
US12280055B2 (en) Combination therapies
JP2022500385A (ja) 組み合わせ療法
JP2022500388A (ja) 組み合わせ療法
CN119031916A (zh) 包含sos1抑制剂和egfr抑制剂的组合疗法
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
JP2024537139A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法
US20250177399A1 (en) Combination therapies
CN118973580A (zh) 包含sos1抑制剂和mek抑制剂的组合疗法
CN117615762A (zh) 组合疗法
HK40101229A (zh) 组合疗法
EP3638690A1 (en) Methods to treat gliomas using a stat3 inhibitor
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
HK40108895A (zh) Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
HK40055040A (en) Combination therapies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination